CAS: 71441-28-6; (E)-4-(2-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydronaphthalen-2-yl)Prop-1-En-1-yl)Benzoic Acid

上下游产品

CAS号71441-09-3 ethyl-p-((E)-2-... | CAS号71441-33-3 2-[4-(1E)-2-(5,... | CAS号619-58-9 对碘苯甲酸 | CAS号17610-21-8 1-(5,5,8,8-四甲基-... | CAS号69251-25-8 1-(5,5,8,8-四甲基-... | CAS号69251-24-7 [1-(5,6,7,8-tet... | CAS号69251-26-9 2-(bromoethyl)-... | CAS号6683-46-1 1,1,4,4-四甲基-1,2... | CAS号6287-86-1 4-甲酰基苯甲酸乙酯

📜4-甲酰基苯甲酸乙酯置于氢氧化钾体系中,用 乙醇 作为反应溶剂,化学反应生成 芳维甲酸
参考文献:De2854354
标题:De2854354

专利信息

专利号:US-6521814-B1
优先权日:1997-12-22
标题:Use of ligands for treatment of diseases responsive to retinoids
发明人：CHAMBON PIERRE; BORRELLI EMILIANA; GHYSELINCK NORBERT B; DUPE VALERIE; MARK MANUEL; METZGER DANIEL
权利人:INST NAT SANTA ET DE LA RECH M; CENTRE NAT RECH SCIENT; UNIV PASTEUR; BRISTOL MYERS SQUIBB CO
摘要:The invention relates to methods for treatment of neurological disease by administering an agent which interacts with a retinoid receptor associated with the neurological disease. The invention is also related to a method of modulating dopamine receptor synthesis by introducing an agent that interacts with a retinoid receptor associated with the dopamine receptor synthesis. The invention is further related to a transgenic animal, e.g., mouse, and mammalian cell line, which is deficient in the normal synthesis of one or more receptors of RARα, β, γ and RXR, and cell line thereof.

专利号:US-8598153-B2
优先权日:2006-09-22
标题 :Method of treatment using fatty acid synthesis inhibitors
发明人：SINGH SHEO B; TOTA MICHAEL R; WANG JUN
权利人:SINGH SHEO B; TOTA MICHAEL R; WANG JUN; MERCK SHARP & DOHME
摘要:The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.

专利号:US-6090810-A
优先权日:1995-09-01
标题:Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
发明人：KLEIN ELLIOTT S; JOHNSON ALAN T; STANDEVEN ANDREW M; BEARD RICHARD L; GILLETT SAMUEL J; DUONG TIEN T; NAGPAL SUNIL; VULIGONDA VIDYASAGAR; TENG MIN; CHANDRARATNA ROSHANTHA A
权利人:ALLERGAN SALES INC
摘要:Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

专利号:US-5877207-A
优先权日:1996-03-11
标 题:Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
发明人：KLEIN ELLIOTT S; JOHNSON ALAN T; STANDEVEN ANDREW M; BEARD RICHARD L; GILLETT SAMUEL J; DUONG TIEN T; NAGPAL SUNIL; VULIGONDA VIDYASAGAR; TENG MIN; CHANDRARATNA ROSHANTHA A
权利人:ALLERGAN SALES INC
摘要:Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

专利号:US-2018170867-A1
优先权日:2015-05-08
标 题:Stereoselective synthesis of 9-cis.13,14-dihydroretinoic acid and its ethyl esters

专利号:US-6316465-B1
优先权日:1998-06-27
标 题:Ophthalmic uses of PPARgamma agonists and PPARgamma antagonists
发明人：PERSHADSINGH HARRIHAR A; LEVY DANIEL E
权利人:PHOTOGENESIS INC
摘要:Methods of treating diseases of ocular tissues expressing the nuclear receptor PPARgamma, by inhibiting the inflammatory response, the neovascularization and angiogenesis, and programmed cell death (apoptosis) in these target tissues, comprising administering to a human or animal in need of treatment an effective amount of a compound that modifies the activity of PPARgamma, or pharmaceutically acceptable salts and solvates thereof.Novel compounds and methods for their synthesis are provided, including a compound having the general structure: